RATIONALE: Asthma exacerbations are commonly precipitated by viral upper respiratory infections (URIs). Vitamin D insufficiency associates with susceptibility to URI in patients with asthma. Trials of vitamin D in adults with asthma with incidence of exacerbation and URI as primary outcome are lacking. OBJECTIVE: To conduct a randomised controlled trial of vitamin D3 supplementation for the prevention of asthma exacerbation and URI (coprimary outcomes). MEASUREMENTS AND METHODS: 250 adults with asthma in London, UK were allocated to receive six 2-monthly oral doses of 3 mg vitamin D3 (n=125) or placebo (n=125) over 1 year. Secondary outcomes included asthma control test and St George's Respiratory Questionnaire scores, fractional exhaled nitric oxide and concentrations of inflammatory markers in induced sputum. Subgroup analyses were performed to determine whether effects of supplementation were modified by baseline vitamin D status or genotype for 34 single nucleotide polymorphisms in 11 vitamin D pathway genes. MAIN RESULTS: 206/250 participants (82%) were vitamin D insufficient at baseline. Vitamin D3 did not influence time to first severe exacerbation (adjusted HR 1.02, 95% CI 0.69 to 1.53, p=0.91) or first URI (adjusted HR 0.87, 95% CI 0.64 to 1.16, p=0.34). No clinically important effect of vitamin D3 was seen on any of the secondary outcomes listed above. The influence of vitamin D3 on coprimary outcomes was not modified by baseline vitamin D status or genotype. CONCLUSIONS: Bolus-dose vitamin D3 supplementation did not influence time to exacerbation or URI in a population of adults with asthma with a high prevalence of baseline vitamin D insufficiency. TRIAL REGISTRATION NUMBER: NCT00978315 (ClinicalTrials.gov). Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
RATIONALE: Asthma exacerbations are commonly precipitated by viral upper respiratory infections (URIs). Vitamin D insufficiency associates with susceptibility to URI in patients with asthma. Trials of vitamin D in adults with asthma with incidence of exacerbation and URI as primary outcome are lacking. OBJECTIVE: To conduct a randomised controlled trial of vitamin D3 supplementation for the prevention of asthma exacerbation and URI (coprimary outcomes). MEASUREMENTS AND METHODS: 250 adults with asthma in London, UK were allocated to receive six 2-monthly oral doses of 3 mg vitamin D3 (n=125) or placebo (n=125) over 1 year. Secondary outcomes included asthma control test and St George's Respiratory Questionnaire scores, fractional exhaled nitric oxide and concentrations of inflammatory markers in induced sputum. Subgroup analyses were performed to determine whether effects of supplementation were modified by baseline vitamin D status or genotype for 34 single nucleotide polymorphisms in 11 vitamin D pathway genes. MAIN RESULTS: 206/250 participants (82%) were vitamin D insufficient at baseline. Vitamin D3 did not influence time to first severe exacerbation (adjusted HR 1.02, 95% CI 0.69 to 1.53, p=0.91) or first URI (adjusted HR 0.87, 95% CI 0.64 to 1.16, p=0.34). No clinically important effect of vitamin D3 was seen on any of the secondary outcomes listed above. The influence of vitamin D3 on coprimary outcomes was not modified by baseline vitamin D status or genotype. CONCLUSIONS: Bolus-dose vitamin D3 supplementation did not influence time to exacerbation or URI in a population of adults with asthma with a high prevalence of baseline vitamin D insufficiency. TRIAL REGISTRATION NUMBER: NCT00978315 (ClinicalTrials.gov). Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Diane R Gold; Augusto A Litonjua; Vincent J Carey; JoAnn E Manson; Julie E Buring; I-Min Lee; David Gordon; Joseph Walter; Georgina Friedenberg; John L Hankinson; Trisha Copeland; Heike Luttmann-Gibson Journal: Contemp Clin Trials Date: 2016-01-16 Impact factor: 2.226
Authors: Adrian R Martineau; Christopher J Cates; Mitsuyoshi Urashima; Megan Jensen; Alex P Griffiths; Ulugbek Nurmatov; Aziz Sheikh; Chris J Griffiths Journal: Cochrane Database Syst Rev Date: 2016-09-05
Authors: David A Jolliffe; Christos Stefanidis; Zhican Wang; Nazanin Z Kermani; Vassil Dimitrov; John H White; John E McDonough; Wim Janssens; Paul Pfeffer; Christopher J Griffiths; Andrew Bush; Yike Guo; Stephanie Christenson; Ian M Adcock; Kian Fan Chung; Kenneth E Thummel; Adrian R Martineau Journal: Am J Respir Crit Care Med Date: 2020-08-01 Impact factor: 21.405
Authors: Paige E Bolcas; Eric B Brandt; Zhonghua Zhang; Jocelyn M Biagini Myers; Brandy P Ruff; Gurjit K Khurana Hershey Journal: J Allergy Clin Immunol Date: 2018-06-21 Impact factor: 10.793
Authors: David A Jolliffe; Lauren Greenberg; Richard L Hooper; Christopher J Griffiths; Carlos A Camargo; Conor P Kerley; Megan E Jensen; David Mauger; Iwona Stelmach; Mitsuyoshi Urashima; Adrian R Martineau Journal: Lancet Respir Med Date: 2017-10-03 Impact factor: 30.700
Authors: Erik B Hysinger; Jeffrey D Roizen; Frank D Mentch; Lyam Vazquez; John J Connolly; Jonathan P Bradfield; Berta Almoguera; Patrick M Sleiman; Julian L Allen; Michael A Levine; Hakon Hakonarson Journal: J Allergy Clin Immunol Date: 2016-08-20 Impact factor: 10.793